Author

B. Lupo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Bertotti· 2 shared E. Grassi· 2 shared E. R. Zanella· 2 shared F. Cottino· 2 shared F. Galimi· 2 shared F. Sassi· 2 shared I. Catalano· 2 shared L. Trusolino· 2 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Bertotti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer

E. Grassi, V. Vurchio, G. D. Cresswell, I. Catalano, B. Lupo, F. Sassi, F. Galimi, S. Borgato, M. Ferri, M. Viviani, S. Pompei, G. Urgese, B. Chen, E. R. Zanella, F. Cottino, , A. Bertotti

The paper measures mutation rates in microsatellite stable colorectal cancers and finds they vary between tumors and increase during metastasis.

bioRxiv · Feb 26, 2024Cancer Biology

XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncology

S. M. Leto, E. Grassi, M. Avolio, V. Vurchio, F. Cottino, M. Ferri, E. R. Zanella, L. Di Blasio, D. Somale, M. Vara-Messler, F. Galimi, F. Sassi, B. Lupo, I. Catalano, M. Pinnelli, , L. Trusolino

XENTURION provides a resource of PDX models and tumoroids from metastatic CRC patients, revealing variable cetuximab responses and identifying therapeutic targets through cross-platform validation.

bioRxiv · Jul 10, 2023Cancer Biology